On 2/04/2020, RAPT Therapeutics filed the paperwork for a $99.3 million offering of its common stock. The South San Francisco based clinical stage company is focused on developing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. RAPT trades on NASDAQ under the symbol “RAPT.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,